Why isn’t LLY talking up Reta in the news?

I think there is a risk of waiting too long to release retatrutide, given the supersonic development of other potentially more effective agents. For example, Bioglutide is a quadruple-receptor agonist and is in phase 2 trials as an oral formulation and as a combined formulation with other GLPs.


Supposedly, Bioglutide works better, faster, with fewer side effects and causes minimal bone/muscle loss. Best of all, it makes you instantly well-hung, that's right, instantly well-hung (ok, I might have dreamt that last part 😎).
Part of me will always be fascinated by what kind of processes take place behind the scenes at big pharma companies making these kinds of decisions. I suspect it's pretty chaotic and and never-ending battle of countless "experts" one-upping each other's expertise and the biggest decisions coming down to a coin toss lol.
 
Top Bottom